Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Patricia A. Koenig"'
Autor:
John M. Timmerman, Israel Lowy, Charles Erlichman, Reiko Yamada, Meena Verma, David J. Inwards, Thomas M. Habermann, Donna Fernando, Brian F. Kabat, Betsy R. LaPlant, Patricia A. Koenig, Sara A. Hurvitz, Stephen M. Ansell
Supplementary Data from Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05daa6099a7fb1bbfa4f7ecaf5ec2b91
https://doi.org/10.1158/1078-0432.22439502.v1
https://doi.org/10.1158/1078-0432.22439502.v1
Autor:
John M. Timmerman, Israel Lowy, Charles Erlichman, Reiko Yamada, Meena Verma, David J. Inwards, Thomas M. Habermann, Donna Fernando, Brian F. Kabat, Betsy R. LaPlant, Patricia A. Koenig, Sara A. Hurvitz, Stephen M. Ansell
Purpose: The growth of non–Hodgkin lymphomas can be influenced by tumor–immune system interactions. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative regulator of T-cell activation that serves to dampen antitumor immune responses. Blocking
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d7002b6eceee0f5b23ebd0954445c1
https://doi.org/10.1158/1078-0432.c.6516957
https://doi.org/10.1158/1078-0432.c.6516957
Autor:
Brian P. O'Neill, Jose S. Pulido, Pamela J. Atherton, Patrick B. Johnston, Levi Pederson, David Schiff, Kurt A. Jaeckle, Patricia A. Koenig, Antonio Omuro, Han W. Tun, Christian Grommes, Thomas E. Witzig, Craig B. Reeder, Lisa M. DeAngelis
Publikováno v:
Blood. 132(21)
The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the
Autor:
Patricia A. Koenig, Charles Erlichman, Thomas E. Witzig, Steven C. Ziesmer, Grzegorz S. Nowakowski, Garth D. Nelson, Daniel A. Nikcevich, Paul J. Kurtin, Hui Tang, Stephen M. Ansell, Peter T. Silberstein, Zhi-Zhang Yang, Deanna M. Grote
Publikováno v:
Leukemia
Follicular lymphoma exhibits intratumoral infiltration by non-malignant T lymphocytes, including CD4+CD25+ regulatory T (T(reg)) cells. We combined denileukin diftitox with rituximab in previously untreated, advanced-stage follicular lymphoma patient
Autor:
Steven C. Ziesmer, Radha Rao, Hui Tang, David J. Inwards, Mamta Gupta, Charles Erlichman, Thomas E. Witzig, Paul J. Kurtin, Stephen M. Ansell, Andrew L. Feldman, Keith Shah, Patricia A Koenig
Publikováno v:
The Lancet. Oncology. 12(4)
Summary Background Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor with single-agent antitumour activity in patients with mantle cell lymphoma. We therefore tested its efficacy and toxicity in combination with rituximab (an antiCD20
Autor:
Thomas M. Habermann, Meena Verma, Patricia A. Koenig, Stephen M. Ansell, Donna Fernando, David J. Inwards, Brian Kabat, Sara A. Hurvitz, Betsy LaPlant, Reiko Yamada, John M. Timmerman, Charles Erlichman, Israel Lowy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(20)
Purpose: The growth of non–Hodgkin lymphomas can be influenced by tumor–immune system interactions. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative regulator of T-cell activation that serves to dampen antitumor immune responses. Blocking
Autor:
Vineta Ghurye, Amylou C. Dueck, Katherine Gano, Patricia A. Koenig, Heidi E. Kosiorek, Veena Fauble, Krisstina L. Gowin, Craig B. Reeder, Ronald Hoffman, John K. Camoriano, Raoul Tibes, John Mascarenhas, Ruben A. Mesa
Publikováno v:
Blood. 126:1618-1618
Introduction: Most myelofibrosis (MF) patients develop anemia during evolution of the disease process predicting decreased survival. Previous studies exploring the effect of danazol for the treatment of anemia in MF demonstrate responses in anemia. I
Autor:
John Mascarenhas, Craig B. Reeder, Veena Fauble, Ruben A. Mesa, Raoul Tibes, Ronald Hoffman, Katherine Gano, John K. Camoriano, Sravan K. Nagi Reddy, Vineta Ghurye, Patricia A. Koenig, Krisstina L. Gowin, Amylou C. Dueck
Publikováno v:
Blood. 124:3206-3206
Introduction: Approximately 75% of myelofibrosis (MF) patients develop anemia during evolution of the disease process predicting decreased survival. Previous studies exploring the effect of danazol in the treatment of anemia in MF demonstrate respons
Autor:
Stephen M. Ansell, Keith Shah, David J. Inwards, Paul J. Kurtin, Hui Tang, Patricia A. Koenig, Thomas E. Witzig
Publikováno v:
Blood. 114:1665-1665
Abstract 1665 Poster Board I-691 Mantle cell lymphoma (MCL) is an aggressive, incurable B-cell malignancy that represents approximately 6% of lymphoma cases. Patients with MCL who relapse after conventional therapy or stem cell transplantation have a